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sUmmArY – fibroadenoma is the most prevalent benign breast tumor. it consists of epithelial 
and stromal components. in general, breast tumors are highly hormonally dependent and growth 
hormone by its physiology may have a possible oncogenic potential. Therefore, the aim of this study 
was to determine the expression of growth hormone and growth hormone receptor in epithelial and 
stromal components of fibroadenomas. study group included 30 randomly chosen fibroadenomas 
from female patients aged between 18 and 69 years. The expression of growth hormone and growth 
hormone receptor was defined in both histologic components of fibroadenomas. growth hormone 
was expressed in 96.7% of both epithelial and stromal components of fibroadenomas, with stronger 
expression in the stromal component. The same percentage of positive reaction (96.7%) was obtained 
in the epithelial component of fibroadenomas for growth hormone receptor expression. only 6.7% 
of stromal components tested for growth hormone receptor were positive. The high expression of 
growth hormone and growth hormone receptor in fibroadenoma tissue indicates their possible role 
in the pathogenesis of this tumor. follow up of patients with high expression of growth hormone 
and growth hormone receptor may be suggested.
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Introduction
fibroadenoma is one of the most common causes 
of a benign lump in the breast1. it may occur at any 
age after puberty but is most frequent in the third de-
cade1. fibroadenoma presents as a painless, solitary, 
firm, slowly growing, mobile, well-defined nodule 
and less frequently it may appear in the form of mul-
tiple nodules. The admixture of stromal and epithelial 
proliferation gives rise to two distinct growth patterns 
of no clinical significance2. both epithelial and strom-
al components can show a wide spectrum of changes 
typically occurring at certain age, such as apocrine 
and squamous metaplasia in the epithelial component 
or focal and diffuse hypercellularity, extensive myx-
oid change and hyalinization with dystrophic calci-
fication, or ossification in the stromal component2. 
ductules vary in configuration; two classic patterns 
are described, intracanalicular when ductules are 
compressed by the stroma into clefts, and pericanali-
cular when the stroma appears to surround ductules in 
a circumferential fashion1.
Pituitary growth hormone (gh) acts on growth 
mainly through the regulation of the insulin-like 
growth factor (igf) system3. it binds with the growth 
hormone receptor (ghr), thus inducing the produc-
tion of igfs (igf-i and igf-ii) in the majority of 
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organs and body tissues. These have autocrine, para-
crine and endocrine actions on metabolism and cell 
proliferation, growth and differentiation3. 
The evidence that gh, igf-i and insulin can pro-
mote and contribute to cancer progression comes from 
various sources, including transgenic and knockout 
mouse models and animal and human cell lines derived 
from cancers4. Cullen et al.5 report that igfs are mito-
gens for many cancer cell types. in breast cancer cells, 
igf-i and igf-ii have both been shown to stimulate 
cell proliferation5. increased ghr level was found in 
colorectal carcinoma and other tumors including breast, 
squamous cell and basal cell carcinoma of the skin and 
melanoma but also preneoplastic lesions6-8. 
There are also epidemiologic data supporting a 
link between gh/igf status and cancer risk. Epide-
miologic studies of patients with acromegaly showed 
an increased risk of colorectal cancer, although the 
risk of other cancers is unproven. Also, a long-term 
follow-up study of children deficient in gh treated 
with pituitary-derived gh has shown an increased 
risk of colorectal cancer9. The risk of prostate cancer is 
increased in men with elevated plasma igf-i, and this 
association is particularly strong in younger men, sug-
gesting that early pathogenesis of prostate cancer may 
be connected with circulating igf-i plasma levels10. 
The aim of this study was to determine the expres-
sion of gh and ghr in the epithelial and stromal 
components of fibroadenomas and to compare the re-
sults both between these two compartments and be-
tween fibroadenomas as a whole.
Materials and Methods
The study was performed on archival material taken 
from the Ljudevit Jurak department of Pathology, ses-
tre milosrdnice University hospital Center. study group 
included 30 randomly chosen fibroadenomas from fe-
male patients aged between 18 and 69 years. specimens 
were fixed in 10% buffered formalin, embedded in par-
affin, cut at 5-μm thickness, and routinely stained with 
hematoxylin and eosin. The diagnosis of fibroadenoma 
was histologically confirmed in all cases. 
immunohistochemical staining for gh (dAKo, 
denmark, dilution 1:400) and ghr (novocastra, 
United Kingdom, dilution 1:100) was performed fol-
lowing LsAb visualization method on dakotechmate 
tm automated machine for immunohistochemical 
staining with streptavidin immunoperoxidase (msiP 
protocol). The expression of gh and ghr was evalu-
ated in both epithelial and stromal components of fi-
broadenomas. The area with the highest number of 
gh/ghr positive cells (‘hot-spot’) was selected un-
der low magnification field (x40), and then the reac-
tion was evaluated under high magnification (x400) 
in 1000 tumor cells.
The results of immunohistochemical staining were 
expressed semiquantitatively using the immunohis-
tochemical staining index (isi), obtained by multiply-
ing the intensity of the staining reaction (ir) and the 
percentage of immunoreactive cells (PrC).
The intensity of the staining reaction was pre-
sented as follows: 0 for negative reaction; 1 for 
weakly positive reaction; 2 for moderately positive 
reaction; and 3 for very strong reaction. The per-
centage of immunoreactive cells was presented as 
follows: 0 for negative reaction; 1 for up to 20% of 
positive cells; 2 for more than 20% but less than 50% 
of positive cells; and 3 for over 50% of positive cells. 
According to the above mentioned conditions, four 
groups were established: isi 0 – negative reaction; isi 
1 – weakly positive reaction (isi product 1-3); isi 2 
– moderately positive reaction (isi product 4-6); and 
isi 3 – very strong reaction (isi product 7-9).
Results
study results are presented in table 1. in the epi-
thelial component of fibroadenoma, gh was expressed 
in 29 of 30 samples (96.7%), with 7 samples showing 
Table 1. Immunohistochemical staining index (ISI) of 
growth hormone (GH) and growth hormone receptor 



































isi 0 = negative reaction; isi 1 = weakly positive reaction; isi 2 = 
moderately positive reaction; isi 3 = very strong reaction
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very strong reaction, 13 samples moderately positive 
and 9 samples weakly positive reaction. in the stromal 
component of fibroadenoma, gh was expressed in 
29 of 30 samples (96.7%), with 20 samples showing 
very strong reaction and 9 samples moderately posi-
tive reaction (fig. 1). in the epithelial component of 
fibroadenoma, ghr was expressed in 29 (96.7%) of 
30 samples, with 8 samples showing very strong reac-
tion, 14 samples showing moderately positive reaction 
and 7 samples showing weakly positive reaction (fig. 
2). in the stromal component of fibroadenoma, ghr 
was practically not detected, with only 2 (6.7%) sam-
ples showing a weakly positive reaction. All positive 
reactions were observed in the cytoplasm of epithelial 
and stromal cells.
Discussion
Like normal breast tissue, benign proliferations 
developing in breast are under a complex system of 
controls by both systemic hormonal and local factors11. 
Although there are several studies that investigated 
the expression of gh and ghr in fibroadenomas, 
none of them included both of these markers. it is 
likely that gh plays an important role in the devel-
opment of fibroadenomas since a number of studies 
have demonstrated an association between the soma-
totropic axis and the risk of developing tumors of the 
mammary gland5,6.
some investigators focused on the local produc-
tion of gh. in the study by raccurt et al.12, in situ 
rt-PCr was used to detect gh mrnA in the tu-
moral and non-tumoral epithelial components and 
also in the cells of reactive stroma. The intensity of 
cellular labeling was always stronger compared with 
that in the adjacent normal tissue irrespective of the 
component observed12. gh protein was also present 
in a significantly higher concentration in proliferative 
disorders of the mammary gland compared with nor-
mal mammary gland12. our study confirmed the high 
presence of gh in fibroadenomas. 
gil-Puig et al.13 found the expression of Pit-1 
mrnA and protein in both normal and tumorous hu-
man breast. The transcription factor pituitary-1 (Pit-
1) is usually mainly expressed in the pituitary gland, 
where it has a critical role in cell differentiation and is 
a transcriptional factor for gh and prolactin (PrL). 
The Pit-1 mrnA levels were found to be significantly 
increased in breast carcinoma compared with normal 
breast13. The increase in the number of cancer cells in 
breast as a consequence of autocrine production of gh 
is a result of both increased mitogenesis and decreased 
apoptosis14. mol et al.15 have come to a conclusion 
that the gene encoding gh is expressed in the mam-
mary gland of a variety of species, including human, 
and that this appears to represent a contribution to 
the molecular explanation of the role of progestins on 
proliferation of mammary epithelium. briefly, there 
Fig. 2. Immunohistochemical staining showing positive 
reaction for growth hormone receptor in the cytoplasm of 
epithelial component of fibroadenoma. (X100)
Fig. 1. Immunohistochemical staining, showing positive 
reaction for growth hormone in the cytoplasm of both epi-
thelial and stromal components of fibroadenoma. (X200)
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is evidence that locally produced gh is involved in 
neoplastic changes in the breast. The study by Kaulsay 
et al.16 showed that the effects of autocrine gh on hu-
man mammary carcinoma cell behavior are mediated 
via the ghr. 
mertani et al.17 found the expression of ghr and 
prolactin receptor (PrLr) genes and their translation 
in epithelial cells of normal, proliferative and neoplas-
tic lesions of the breast including fibroadenoma, where 
ghr was detected using immunohistochemistry both 
in the epithelial and stromal components. stromal 
cells were found sometimes positive, but the label-
ing intensity was always weaker than for neoplastic 
epithelial cells, including fibroadenomas17. This corre-
lates with our results where only 2 stromal samples of 
fibroadenoma tissue were positive for ghr compared 
to 29 positive epithelial samples. gebre-medhin et 
al.6 demonstrated greater ghr expression in breast 
carcinoma than in normal breast tissue. detecting the 
ghr by PCr, 75% of the samples (36 of 48) were 
evidently positive6. 
some studies were focused on circulating gh 
and/or igf in order to unfold the pathogenesis of 
breast tumors. hankinson et al.18 and toniolo et al.19 
found a positive correlation between circulating igf-
i concentration and the risk of breast cancer among 
premenopausal but not postmenopausal women. on 
the contrary, literature data show no statistically sig-
nificant differences in the expression of estrogen and 
progesterone receptors in invasive ductal breast car-
cinoma between premenopausal and postmenopausal 
women20. The results obtained by sawyer et al.21 re-
vealed igf-i and igf-ii overexpression in fibroade-
nomas and the most similar phylloides tumors, which 
seems to be important in their pathogenesis. 
in conclusion, it is obvious that there is stronger ex-
pression of gh and ghr in fibroadenomas and other 
tumorous breast tissues than in normal breast tissue, 
which was confirmed in this study. our results show 
that there is a higher gh expression in the stromal 
than in the epithelial component of fibroadenoma. 
Likewise, ghr is mostly expressed in the epithelial 
component, while there is almost no expression in the 
stromal component, rendering epithelial component 
the probable main pathway for gh influence.
based on our and previous studies, it can be con-
cluded that the pathogenesis of breast tumors, such as 
fibroadenoma, is highly hormone dependent. follow 
up of patients with high expression of gh and ghr 
may be suggested. further research in this area may 
hopefully lead us to more efficient hormonally depen-
dent therapy.
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sažetak
EKsPrEsiJA hormonA rAstA i rECEPtorA hormonA rAstA Kod fibroAdEnomA doJKE
T. Leniček, D. Kasumović, E. Štajduhar, T. Džombeta, Z. Jukić  i B. Krušlin
fibroadenom je najčešća dobroćudna novotvorina dojke, a sastoji se od epitelne i stromalne komponente. Uzimajući 
u obzir hormonsku osjetljivost tumora dojke, te potencijalni onkogeni potencijal hormona rasta, cilj našega rada bio je 
utvrditi ekspresiju hormona rasta i receptora hormona rasta u epitelnoj i stromalnoj komponenti fibroadenoma. U studiju je 
bilo uključeno 30 nasumice odabranih fibroadenoma nastalih u žena u dobi od 18 do 69 godina. Ekspresija hormona rasta 
i receptora hormona rasta određivana je u obje histološke komponente fibroadenoma. Ekspresija hormona rasta nađena je u 
96,7% epitelne i stromalne komponente, uz jaču izraženost ekspresije u stromalnoj komponenti. Ekspresija receptora hor-
mona rasta u epitelnoj je komponenti također iznosila 96,7%, a u stromalnoj samo 6,7%. Visoka ekspresija hormona rasta 
i receptora hormona rasta u fibroadenomima označava potencijalnu ulogu ovoga hormona u patogenezi ispitivane bolesti, 
te bi se u bolesnica ove skupine mogle preporučiti češće kliničke kontrole. 
Ključne riječi: Fibroadenom; Hormon rasta; Receptor hormona rasta 

